Search 

医疗专业精品投行

A CAP, CLIA And AABB certified clinical lab specialized in genetic and molecular diagnosis

Medprin focuses on RD and sales and marketing of implantable medical devices with products in general surgery and neurosurgery. Current Medprin is actively looking for promising startups /team with matching technology/products that Medprin can both invests financially and develops long term partnership.

After 35 years of development, the company has established an industry pattern integrating science, industry and trade led by international trade, supported by the pharmaceutical industry, and linked by pharmaceutical business, covering the whole industrial chain including R&D, production, distribution, logistics, import and export trade, academic promotion, and technical services.

Mend Biotech’s full name is Mend Biotechnology Incorporation, and its English name is Mend Biotech Inc. ( MBT). It is a multinational research institution focusing on the field of regenerative medicine to treat various skeletal-related diseases. The founding team consists of Professors and Scientists in Cedars-Sinai Medical center, UCLA and Harvard University and the kick school of medicine in USC, and the CEO of a multinational biotechnology company. In June 2020, MBT settled in CHENGDU TianFu international Bio-town as a key project introduced by Chengdu High-tech zone government. MBT received 13.5 million Chinese yuan in seed round investment by Mr. chen keming, chairman of keming noodle industry, a listed company in China. A follow on angel round is expected to generate an investment of 40 million. GMP and cGMP lab are currently under construction in both China and US.

MSA manages over $1.5 billion and invests in global leading early and growth-stage technology-enabled companies.

TransThera Biosciences is a Nanjing based biotech, founded in 2016, focusing on research and development of small molecules in oncology, inflammation, and cardiovascular diseases. Four assets have entered into global clinical development in past 4 years.

关注科技驱动的商业创新，TMT、大健康、生物技术

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.